Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Should Issue Pediatric Antidepressant Trial Summaries, Rep. Waxman Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The congressman's letter requests the immediate release of data for drugs that gained six months of additional exclusivity under the Best Pharmaceuticals for Children Act. While seven companies have gained exclusivity extensions for antidepressants, data on only two are available, he says.

You may also be interested in...



Antidepressant Manufacturers’ Trial Information Requested By Senate Cmte.

Finance Chairman Grassley asks eight manufacturers for list of all pediatric antidepressant trials, including completion, publication and FDA submission information. Grassley expresses concern that the firms may not have provided FDA with all the information “at their disposal.”

Antidepressant Manufacturers’ Trial Information Requested By Senate Cmte.

Finance Chairman Grassley asks eight manufacturers for list of all pediatric antidepressant trials, including completion, publication and FDA submission information. Grassley expresses concern that the firms may not have provided FDA with all the information “at their disposal.”

Clinicaltrials.gov: Rep. Waxman Wants PhRMA To Describe Steps To Improve Compliance

Waxman takes issue with PhRMA’s failure to appear at a recent House hearing to discuss FDA’s clinical trial registry. He asks the association to submit documents it has sent to member companies regarding compliance with the submission requirement.

Topics

UsernamePublicRestriction

Register

PS060057

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel